VA
KRYS icon

Vident Advisory’s Krystal Biotech KRYS Stock Holding History

Vident Advisory’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$727K Buy
1,956
+342
+21% +$102K 0.01% 1159
2026
Q1 		$417K Buy
1,614
+120
+8% +$31.9K ﹤0.01% 1350
2025
Q4 		$368K Buy
1,494
+76
+5% +$16K ﹤0.01% 1299
2025
Q3 		$250K Sell
1,418
-564
-28% -$84.4K ﹤0.01% 1479
2025
Q2 		$272K Sell
1,982
-805
-29% -$118K ﹤0.01% 1350
2025
Q1 		$502K Buy
2,787
+295
+12% +$49.6K 0.01% 1028
2024
Q4 		$390K Sell
2,492
-83
-3% -$14.7K 0.01% 1068
2024
Q3 		$469K Buy
2,575
+610
+31% +$118K 0.01% 954
2024
Q2 		$361K Buy
1,965
+549
+39% +$92.2K 0.01% 1052
2024
Q1 		$252K Buy
+1,416
New +$197K 0.01% 1113

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vident Advisory's KRYS Position: Q2 2026 in Review

Vident Advisory increased its Krystal Biotech (KRYS) stake by 21% in Q2 2026, buying an estimated $102K and bringing the position to 1,956 shares worth $727K. The position accounts for 0.01% of the portfolio, ranked #1159.

Vident Advisory first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vident Advisory held 1,956 shares of Krystal Biotech worth $727K as of Q2 2026.
  • Vident Advisory bought 342 Krystal Biotech shares in Q2 2026, an estimated $102K.
  • Krystal Biotech made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1159 holding.
  • Vident Advisory first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.